LIXTE (LIXT) director cancels 25K options, receives 25K RSUs vesting immediately

Rhea-AI Filing Summary

LIXTE BIOTECHNOLOGY HOLDINGS, INC. director Michael Andrew Holloway restructured his equity compensation on April 15, 2026. He disposed of options to purchase 25,000 shares of common stock back to the company and, in exchange, received 25,000 restricted share units (RSUs).

Each RSU represents a right to receive one share of common stock, and all 25,000 RSUs vested immediately upon grant, subject to continued service conditions in the plan documents. Following these transactions, Holloway directly holds 25,000 shares of common stock, reflecting this grant-and-cancel structure rather than an open-market trade.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Holloway Michael Andrew

Role Director

Type	Security	Shares	Price	Value
Disposition	Options to Purchase Common Stock	25,000	$0.00	--
Grant/Award	Common Stock	25,000	$0.00	--

Holdings After Transaction: Options to Purchase Common Stock — 0 shares (Direct); Common Stock — 25,000 shares (Direct)

Footnotes (1)

1. On April 15, 2026, the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026 between the Issuer and the Reporting Person, the 25,000 options (the "Options") granted to the Reporting Person on August 15, 2025. In exchange for the Options, the Reporting Person received 25,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 25,000 RSUs vest immediately upon grant. The canceled Options provided for vesting 50% on the effective date, the remaining 50% vesting 12.5% on December 31, 2025 and on the last day of each subsequent calendar quarter until fully vested.

Key Figures

Options canceled: 25,000 options Option exercise price: $3.59 per share RSUs granted: 25,000 RSUs +2 more

5 metrics

Options canceled 25,000 options Disposition to issuer on April 15, 2026

Option exercise price $3.59 per share Canceled options originally granted August 15, 2025

RSUs granted 25,000 RSUs Granted April 15, 2026 under 2020 Stock Incentive Plan

Shares held after 25,000 shares Common stock directly owned following transactions

Option expiration August 15, 2030 Original expiration date of canceled options

Key Terms

Stock Option Cancellation Agreement, restricted share units, 2020 Stock Incentive Plan, contingent right, +1 more

5 terms

Stock Option Cancellation Agreement financial

"the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026"

restricted share units financial

"In exchange for the Options, the Reporting Person received 25,000 restricted share units ("RSUs")"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

2020 Stock Incentive Plan financial

"granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan"

contingent right financial

"Each RSU represents a contingent right to receive one share of common stock upon vesting"

vesting financial

"The 25,000 RSUs vest immediately upon grant"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Holloway Michael Andrew

(Last) (First) (Middle)

433 PLAZA REAL, SUITE 275

(Street)

BOCA RATON FLORIDA 33432

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LIXTE BIOTECHNOLOGY HOLDINGS, INC. [ LIXT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/15/2026		A		25,000	A	(1)	25,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Purchase Common Stock	$3.59	04/15/2026		D			25,000	(2)	08/15/2030	Common	25,000	(1)	0	D

Explanation of Responses:

1. On April 15, 2026, the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026 between the Issuer and the Reporting Person, the 25,000 options (the "Options") granted to the Reporting Person on August 15, 2025. In exchange for the Options, the Reporting Person received 25,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 25,000 RSUs vest immediately upon grant.

2. The canceled Options provided for vesting 50% on the effective date, the remaining 50% vesting 12.5% on December 31, 2025 and on the last day of each subsequent calendar quarter until fully vested.

	/s/ Michael Holloway	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did LIXT director Michael Holloway report in this Form 4 for LIXT?

Michael Holloway reported an equity compensation restructuring. He surrendered options for 25,000 shares and received 25,000 restricted share units that vested immediately, resulting in direct ownership of 25,000 LIXTE BIOTECHNOLOGY HOLDINGS, INC. common shares after the transaction.

How many LIXT options did Michael Holloway cancel in the reported transaction?

He canceled options to purchase 25,000 shares of LIXTE BIOTECHNOLOGY common stock. These options had an exercise price of $3.59 per share and were originally granted on August 15, 2025, with vesting spread over several dates before the cancellation.

What did Michael Holloway receive in exchange for the canceled LIXT stock options?

In exchange for canceling 25,000 stock options, Michael Holloway received 25,000 restricted share units. Each RSU represents a contingent right to one LIXTE BIOTECHNOLOGY common share under the 2020 Stock Incentive Plan and the related April 15, 2026 award agreement.

When did Michael Holloway’s new LIXT restricted share units vest?

All 25,000 restricted share units granted to Michael Holloway vested immediately on April 15, 2026. The RSUs were subject to continued service conditions, but the vesting itself occurred upon grant according to the Form 4 footnote disclosure.

How many LIXTE BIOTECHNOLOGY shares does Michael Holloway own after this Form 4 event?

Following the reported transactions, Michael Holloway directly holds 25,000 shares of LIXTE BIOTECHNOLOGY common stock. This position reflects the immediate vesting and share delivery associated with the 25,000 restricted share units granted in exchange for the canceled options.

What was the exercise price and expiration of the canceled LIXT stock options?

The canceled options had a conversion or exercise price of $3.59 per share and an expiration date of August 15, 2030. They were originally scheduled to vest 50% at grant and 12.5% on subsequent quarter-end dates until fully vested.